Objectives:Ventilator-associated pneumonia is the first or second most commonly diagnosed nosocomial infection in the PICU. Centers for Disease Control diagnostic criteria include clinical signs or symptoms in conjunction with a “positive” tracheal aspirate, defined as more than 104 colony-forming u

The lack of specificity of tracheal aspirates in the diagnosis of pulmonary infection in intubated children

Aim While ventilator-associated pneumonia (VAP) remains frequent in Pediatric ICU, there is no gold standard for diagnosis. Methodology We conducted a systematic PUBMED analysis (January 1990-January 2017) searching original, full-length studies addressing only pediatric patients; for VAP diagnosis, only those comparing different diagnostic methods and for VAP prevention those implementing preventive measures. Results Among 367 articles, 17 and 16 were analyzed for diagnosis and prevention, respectively. For diagnosis, 13 studies used CDC criteria; whereas, 14 assessed algorithms: clinical pulmonary index score, ventilator-associated events and biomarkers. Among five randomized trials assessing preventive strategies one found a role of probiotics. Ventilator-care bundles reduced VAP rates. Conclusion Absence of diagnostic gold standard impedes comparison of current approaches and preventive strategies.

Ventilator-associated pneumonia in neonates and children: a systematic analysis of diagnostic methods and prevention.

Acute respiratory distress syndrome (ARDS) is common among mechanically ventilated children and accompanies up to 30% of all pediatric intensive care unit deaths. Though ARDS diagnosis is based on clinical criteria, biological markers of acute lung damage have been extensively studied in adults and children. Biomarkers of inflammation, alveolar epithelial and capillary endothelial disruption, disordered coagulation, and associated derangements measured in the circulation and other body fluids, such as bronchoalveolar lavage, have improved our understanding of pathobiology of ARDS. The biochemical signature of ARDS has been increasingly well described in adult populations, and this has led to the identification of molecular phenotypes to augment clinical classifications. However, there is a paucity of data from pediatric ARDS (pARDS) patients. Biomarkers and molecular phenotypes have the potential to identify patients at high risk of poor outcomes, and perhaps inform the development of targeted therapies for specific groups of patients. Additionally, because of the lower incidence of and mortality from ARDS in pediatric patients relative to adults and lack of robust clinical predictors of outcome, there is an ongoing interest in biological markers as surrogate outcome measures. The recent definition of pARDS provides additional impetus for the measurement of established and novel biomarkers in future pediatric studies in order to further characterize this disease process. This chapter will review the currently available literature and discuss potential future directions for investigation into biomarkers in ARDS among children.

/pdf/biomarkers-in-pediatric-ards-future-directions-3a57gsrlz3.pdf

Biomarkers in Pediatric ARDS: Future Directions

Objective:Suspected ventilator-associated infection is the most common reason for antibiotics in the PICU. We sought to characterize the clinical variables associated with continuing antibiotics after initial evaluation for suspected ventilator-associated infection and to determine whether clinical

Pediatric Ventilator-Associated Infections: The Ventilator-Associated INfection Study.

The role of flexible bronchoscopy and bronchoalveolar lavage (BAL) for the care of children with airway and pulmonary diseases is well established, with collected BAL fluid most often used clinically for microbiologic pathogen identification and cellular analyses. More recently, powerful analytic research methods have been used to investigate BAL samples to better understand the pathophysiological basis of pediatric respiratory disease. Investigations have focused on the cellular components contained in BAL fluid, such as macrophages, lymphocytes, neutrophils, eosinophils, and mast cells, as well as the noncellular components such as serum molecules, inflammatory proteins, and surfactant. Molecular techniques are frequently used to investigate BAL fluid for the presence of infectious pathologies and for cellular gene expression. Recent advances in proteomics allow identification of multiple protein expression patterns linked to specific respiratory diseases, whereas newer analytic techniques allow for investigations on surfactant quantification and function. These translational research studies on BAL fluid have aided our understanding of pulmonary inflammation and the injury/repair responses in children. We review the ethics and practices for the execution of BAL in children for translational research purposes, with an emphasis on the optimal handling and processing of BAL samples.

Translational research in pediatrics III: bronchoalveolar lavage.

Rationale

The pathobiology of ventilator-associated pneumonia (VAP) in children is poorly understood; investigation has been limited by lack of universally applied diagnostic criteria and reliable biomarkers for this condition.



Objectives

We evaluated the clinical pulmonary infection score (CPIS) in diagnosing VAP and prospectively characterized the relationship between surfactant protein-D (SP-D) metabolism and VAP.



Methods

Children admitted to an Egyptian PICU requiring intubation were screened for the absence of primary pulmonary pathology. Thirty-nine children underwent two evaluations: during the first 36 hr following intubation and after 4 days of mechanical ventilation. During both, bronchoalveolar lavage fluid (BALF) was obtained for culture and SP-D assay. CPIS was computed during the second evaluation.



Results

Optimum performance of the CPIS against BALF culture occurred at a cutoff value of 6, (ROC AUC of 0.89 ± 0.05). Children who developed VAP had significantly higher SP-D levels, both preceding (129.9 ± 33.5 ng/ml at the 1st BAL)—and following positive BALF culture (249.5 ± 51.2 ng/ml at the 2nd BAL), compared to children whose BALF remained sterile (62.6 ± 18.1 ng/ml and 64.9 ± 9.4 ng/ml; P < 0.001). This increase in SP-D levels was most evident in children infected with Pseudomonas aeruginosa compared to children with Klebsiella pneumonia or S. aureus.



Conclusions

The CPIS performed well against BALF culture. We observed a bacterial species-specific difference in SP-D levels in children who developed VAP; this change preceded detection of infection by CPIS or BALF culture. Pediatr Pulmonol. 2012; 47:292–299. © 2011 Wiley Periodicals, Inc.

Magid A. Abd-ElFattah

Papers

Evolution of surfactant protein-D levels in children with ventilator-associated pneumonia.